Mar 02, 2021 10:30am EST Lixte Biotechnology Announces the Closing of $4.19 Million Registered Direct Offering
Feb 24, 2021 9:35am EST Lixte Biotechnology to Present Its Anti-Cancer Therapy Enhancer LB-100 at the Virtual H.C. Wainwright Global Life Sciences Conference
Jan 19, 2021 9:35am EST Lixte Biotechnology and City of Hope to Initiate Phase 1b Clinical Trial of Lixte’s Lead Compound LB-100 to Treat Small Cell Lung Cancer
Dec 01, 2020 12:30pm EST Lixte Biotechnology Holdings, Inc. Announces Closing of Public Offering and Uplisting to Nasdaq
Nov 25, 2020 8:30am EST Lixte Biotechnology Holdings, Inc. Announces Pricing of $5,700,000 Public Offering; Uplisting to Nasdaq Capital Market and Reverse Stock Split
Aug 18, 2020 9:35am EDT The Foundation for Angelman Syndrome Therapeutics (FAST) and Lixte Biotechnology Collaborate to Support the Preclinical Study of Lixte’s Protein Phosphatase 2A Inhibitor, LB-100, as a Possible Treatment for Angelman Syndrome
Jul 21, 2020 9:35am EDT Lixte Biotechnology Holdings, Inc. Announces The Appointment Of Internationally Recognized Clinical Cancer Investigator, James S. Miser MD, As Chief Medical Officer
Apr 30, 2020 10:30am EDT Lixte Biotechnology’s PP2A Inhibitor, LB-100, Enhances the Effectiveness of PD1 Immune Blockade in Mouse Models of Glioblastoma Brain Tumors
Dec 04, 2019 9:35am EST First Two Patients Enrolled in National Cancer Institute Trial of the Ability of Lixte Biotechnology’s LB-100 to Enter Recurrent Malignant Brain Tumors
